/EVO

EVO Stock - Evotec SE

Q: What is the analyst price target for EVO?

Analyst price target information is not currently available for EVO.

Q: What is EVO's market cap?

Market capitalization information is not currently available for EVO.

Healthcare|Drug Manufacturers - Specialty & Generic|NASDAQ

$3.87+2.93%

+$0.11 (+2.93%) • Jan 13

GoAI Score

Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.

BUY

Medium Confidence

Momentum

Momentum Score

Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.

Sentiment

Sentiment Score

Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).

100

Risk Score

Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.

Price Target

Average analyst price target from the last quarter. Shows expected upside/downside from current price.

+80.9%upside

Target: $7.00

AI Analysis PreviewPremium

Real-time AI-powered market analysis

Precise entry/exit price targets

Risk assessment & position sizing

Unlock GoAI Insights for EVO

Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.

Buy/Sell Signals

94% win rate on Alpha signals

Deep Analysis

Institutional-grade thesis

Real-Time Alerts

SMS & push notifications

Risk Scoring

Multi-factor analysis

Free 14-day trial • No credit card required

Financial Statements

Revenue & Profitability Trend

FY2020

FY2021

FY2022

FY2023

FY2024

← Swipe to see more →

Revenue

Net Income (Profit)

Net Loss

Key Metrics

Market CapN/A

P/E RatioN/A

Beta1.07

52W High$4.80

52W Low$2.84

Avg VolumeN/A

Income Statement (Fiscal Year)

Metric	FY2024	FY2023	FY2022	FY2021	FY2020
Revenue	$796.97M	$781.43M	$751.45M	$618.03M	$500.92M
Gross Profit	$114.88M	$175.05M	$174.06M	$151.54M	$125.74M
Gross Margin	14.4%	22.4%	23.2%	24.5%	25.1%
Operating Income	$-142,522,000	$-47,507,000	$20.85M	$41.00M	$48.56M
Net Income	$-196,078,000	$-83,913,000	$-175,655,000	$215.51M	$6.28M
Net Margin	-24.6%	-10.7%	-23.4%	34.9%	1.3%
EPS	$-0.56	$-0.23	$-0.49	$0.65	$0.02

Company Overview

Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as diabetes and complications of diabetes, fibrosis, infectious diseases, CNS diseases, oncology, pain and inflammation, immunology, rare diseases, respiratory diseases, and women's health. It has collaboration agreements with Bayer AG; Lilly; Chinook Therapeutics; Novo Nordisk A/S; Galapagos; Pfizer Inc.; CONBA Pharmaceutical Co., Ltd.; Bristol Myers Squibb Company; Zhejiang JingXin Pharmaceutical Co., Ltd; Kazia Therapeutics; Apeiron Biologics; and Takeda Pharmaceuticals. The company was formerly known as Evotec AG and changed its name to Evotec SE in April 2019. Evotec SE was incorporated in 1993 and is headquartered in Hamburg, Germany.

Visit Website

Earnings History & Surprises

EVO

Beat Rate

Last 16 quarters

Avg Surprise

-207.0%

EPS vs Estimate

Beats / Misses

1/15

Last 12 quarters

Latest EPS

$-0.14

Q4 2025

EPS Surprise History

Q1 24

-66.7%

$-0.05vs$-0.03

Q2 24

-49.5%

$-0.05vs$-0.03

Q3 24

-222.2%

$-0.29vs$-0.09

Q4 24

-50.0%

$-0.12vs$-0.08

Q2 25

-768.2%

$-0.12vs$0.02

Q2 25

-77.3%

$-0.19vs$-0.11

Q3 25

+19.9%

$-0.14vs$-0.18

Q4 25

-1.4%

$-0.14vs$-0.14

Beat Estimate

Missed Estimate

Quarterly EPS Details

Period	Report Date	Estimated EPS	Actual EPS	Surprise	Result
Q4 2025	Nov 5, 2025	$-0.14	$-0.14	-1.4%	✗ MISS
Q3 2025	Aug 13, 2025	$-0.18	$-0.14	+19.9%	✓ BEAT
Q2 2025	May 6, 2025	$-0.11	$-0.19	-77.3%	✗ MISS
Q2 2025	Apr 17, 2025	$0.02	$-0.12	-768.2%	✗ MISS
Q4 2024	Nov 6, 2024	$-0.08	$-0.12	-50.0%	✗ MISS
Q3 2024	Aug 14, 2024	$-0.09	$-0.29	-222.2%	✗ MISS
Q2 2024	May 22, 2024	$-0.03	$-0.05	-49.5%	✗ MISS
Q1 2024	Feb 26, 2024	$-0.03	$-0.05	-66.7%	✗ MISS
Q4 2023	Nov 8, 2023	$-0.05	$-0.12	-140.0%	✗ MISS
Q3 2023	Aug 29, 2023	$-0.04	$-0.04	-10.9%	✗ MISS
Q2 2023	May 12, 2023	$0.10	$-0.08	-180.0%	✗ MISS
Q1 2023	Mar 29, 2023	$0.10	$-0.13	-230.0%	✗ MISS
Q4 2022	Nov 9, 2022	$0.08	$-0.26	-419.5%	✗ MISS
Q3 2022	Aug 11, 2022	$-0.02	$-0.08	-375.1%	✗ MISS
Q2 2022	May 11, 2022	$0.06	$-0.23	-483.3%	✗ MISS
Q2 2022	Apr 12, 2022	$0.07	$-0.11	-257.1%	✗ MISS
Q4 2021	Nov 11, 2021	—	$0.95	—	—
Q3 2021	Aug 11, 2021	—	$0.43	—	—
Q2 2021	May 11, 2021	—	$0.38	—	—
Q1 2021	Mar 25, 2021	—	$0.00	—	—

Frequently Asked Questions about EVO

What is EVO's current stock price?

Evotec SE (EVO) is currently trading at $3.87 per share. The stock has moved +2.93% today.

What is the analyst price target for EVO?

The average analyst price target for EVO is $7.00, based on 1 analyst.

What sector is Evotec SE in?

Evotec SE operates in the Healthcare sector, specifically within the Drug Manufacturers - Specialty & Generic industry. The company is traded on the NASDAQ exchange.

What is EVO's market cap?

Evotec SE has a market capitalization of $1.37 billion, making it a small-cap company.

Does EVO pay dividends?

No, Evotec SE does not currently pay a dividend to shareholders.